rc 3095 has been researched along with Ovarian Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Armatis, P; Chatzistamou, I; Schally, AV; Sun, B; Szepeshazi, K | 1 |
| Arencibia, JM; Chatzistamou, I; Groot, K; Hebert, F; Schally, AV; Szepeshazi, K | 1 |
2 other study(ies) available for rc 3095 and Ovarian Neoplasms
| Article | Year |
|---|---|
Inhibition of growth of OV-1063 human epithelial ovarian cancers and c- jun and c- fos oncogene expression by bombesin antagonists.
Topics: Animals; Antineoplastic Agents; Bombesin; Cell Division; Epithelium; Female; Gastrin-Releasing Peptide; Gene Expression; Genes, fos; Genes, jun; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Peptide Fragments; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Receptors, Bombesin; RNA, Messenger; Tumor Cells, Cultured | 2000 |
Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix.
Topics: Adenocarcinoma, Clear Cell; Animals; Antineoplastic Agents, Hormonal; Bombesin; ErbB Receptors; Female; Gastrin-Releasing Peptide; Gene Expression Regulation, Neoplastic; Gonadotropin-Releasing Hormone; Humans; Luteinizing Hormone; Mice; Mice, Nude; Neoplasm Proteins; Ovarian Neoplasms; Peptide Fragments; Receptors, Bombesin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Specific Pathogen-Free Organisms; Xenograft Model Antitumor Assays | 2001 |